Short answer
Bicara Therapeutics Inc. (BCAX) filed an 8-K current report with the SEC on August 11, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results and business updates announced for quarter ended June 30, 2026.
Bicara Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and business updates announced for quarter ended June 30, 2026
- Full results and operational details available in Exhibit 99.1 press release
- Investor focus: quarterly performance, cash position and clinical-development updates in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Leadership succession: Ryan Cohlhepp becomes CEO January 1, 2027, while Claire Mazumdar transitions to Vice Chair and Strategic Advisor
- FORTIFI-HN01 pivotal trial expected substantially enrolled by year-end, targeting interim topline results in mid-2027
- Cash, equivalents and marketable securities $497.3M, supporting operations into the first half of 2029 under current plans
- Second-quarter net loss $55.4M, versus $27.4M in 2025, reflecting sharply higher clinical and commercialization investment
- FORTIFI-FLEX initiated to test 1,500mg weekly loading followed by 2,250mg every three weeks with pembrolizumab
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bicara Therapeutics Inc. 8-K filings
Get the next BCAX 8-K as it lands
Follow BCAX for push alerts, or ask the research agent what this filing means.